I’ve been closely following the arena of stem cells for COVID-19 since the pandemic broke including the efforts of Mesoblast. Mesoblast unlikely to meet primary endpoints in Phase III COVID trial Now, the firm got bad news as its DSMB reported that they are unlikely to meet the primary endpoint for their Phase III trial of their stem cell product for COVID-19 based on preliminary analyses. Mesoblast had set the endpoint as a “43% reduction in mortality at 30 days for treatment with remestemcel-L.” ...Read More

The post Mesoblast stock hit on gloomy data on stem cells for COVID-19 appeared first on The Niche.

Read Original